Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 New Aimovig Medication Approved Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. […]
New Aimovig Medication Approved Read More »
Ten years and a billion euros. This is the time and average cost for a drug to complete the process that goes from its initial discovery to being sold at a pharmacy. Considering this data, it´s not difficult to imagine the manufacture of a drug as an obstacle course in which only a few molecules
This is how a medicine is manufactured (from the laboratory to the pharmacy) Read More »
Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes
Novartis’ Migraine prevention therapy is closer to being approved Read More »
First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity
First monoclonal antibody therapy for prevention of migraine Read More »
The following article shows a clear example of best practices at work and how important it is to have employees happy and satisfied at the workspace in order to have them working at their maximum possibilities. The pharmaceutical laboratory AbbVie recognizes that caring for the health and the well-being of its employees has an impact on
A laboratory that takes care of its employees Read More »
Cluster headache: Galcanezumab Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks. In weekly clusters compared to placebo during the weeks
Cluster headache: Galcanezumab Read More »
The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a
New Drug Offers Hope to Millions With Severe Migraines Read More »
CGRP as the target of new migraine therapies — successful translation from bench to clinic You can now download the document here: —–> CGRP as the target of new migraine therapies — successful translation from bench to clinic Treatment of migraine is on the cusp of a new era with the development of drugs that target
CGRP as the target of new migraine therapies Read More »
Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone estrogen affect cells in the brain. Of the more than 38 million Americans who experience migraine headaches, 28 million are women. Compared to men, women
Potential source of gender differences in migraines Read More »
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar
New measures to avoid valproate exposure in pregnancy Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
